|
biomedicina slovenica |
pr=Biganzoli : 21
-
Efficace Fabio; Biganzoli Laura; Piccart Martine; Čufer Tanja
Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer
2004 ►
-
Lusa Lara; Mc Shane Lisa M; Reid James F; De Cecco Loris; Ambrogi Federico; Biganzoli Elia; Gariboldi Manuela; Pierotti Marco A
Challenges in projecting clustering results across gene expression profiling data sets
2007 ►
-
Lusa Lara; McShane Lisa M; Reid James F; De Cecco Loris; Ambrogi Federico; Biganzoli Elia; Gariboldi Manuela; Pierotti Marco A
Challenges in projecting clustering results across gene expression-profiling datasets
2007 ►
-
Bottomley Andrew; Biganzoli Laura; Čufer Tanja; Coleman Robert E; Coens Cornel; Efficace Fabio; Calvert Hilary Allan; Gamucci Teresa; Twelves Chris; Fargeot Pierre; Piccart Martine
Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European organization for research and treatment of cancer breast cancer group, Investigational drug branch for breast cancer and the New drug development group study
2004 ►
-
Atalay G; Dirix L; Biganzoli L; Beex L; Nooij M; Cameron D; Lohrisch C; Čufer T; Lobelle JP; Mattiaci MR
The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'
2004 ►
-
Atalay G; Biganzoli L; Renard F; Paridaens R; Čufer T; Coleman R; Calvert AH; Gamucci T; Minisini A; Therasse P
Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trials
2003 ►
-
Paridaens R; Dirix L; Lohrisch C; Beex L; Nooij M; Cameron D; Biganzoli L; Čufer T; Duchateau L; Hamilton A; Lobelle JP; Piccart M
Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer
2003 ►
-
Paridaens R; Dirix L; Beex L; Nooij MN; Čufer T; Lohrisch C; Biganzoli L; van Hoorebeeck I; Duchateau L; Lobelle JP; Piccart M
Promising results with exemestane in the first-line treatment of metastatic breast cancer: a randomized phase II EORTC trial with a tamoxifen control
2000 ►
-
Bonnefoi H; Biganzoli L; Mauriac L; Čufer T; Schaefer P; Atalay G; Piccart M
An EORTC phase I study of capecitabine (xeloda) in combination with fixed doses of cyclophosphamide and epirubicin (cex) as primary treatment for large operable or locally advanced/inflammatory breast cancer
2003 ►
-
Biganzoli Laura; Čufer Tanja; Bruning Peter; Coleman Robert E; Duchateau Luc; Rapoport Bernardo; Nooij Marianne; Delhaye Francois; Miles D; Sulkes Aaron
Doxorubicin-paclitaxel: a safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European organization for research and treatment of cancer multicenter trial
2003 ►
-
Awada A; Biganzoli L; Čufer T; Beex L; Lohrisch C; Batter V; Hamilton A; Nooij M; Piccart M
An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes
2002 ►
-
Biganzoli L; Čufer T; Bruning P; Coleman R; Duchateau L; Calvert AH; Gamucci T; Twelves C; Fargeot P; Epelbaum R; Lohrisch C; Piccart MJ
Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European organization for research and treatment of cancer 10961 multicenter phase III trial
2002 ►
-
Biganzoli L; Bonnefoi H; Mauriac L; Čufer T; Kabanga-Ngalula E; Hebert D; Piccart M
Cyclophosphamide (C) - Epirubicine (E) - Capecitabine (X) combination, CEX: a safe and active regimen in the treatment of locally advanced/inflammatory (LA/I) or large operable (LO) breast cancer (BC). An EORTC-IDBBC study
2001 ►
-
Bonnefoi H; Biganzoli L; Čufer T; Mauriac L; Hamilton A; Schaefer P; Picart M
An EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancer
2001 ►
-
Dirix L; Piccart MJ; Lohrisch C; Beex L; Nooij M; Cameron D; Biganzoli L; Čufer T; Yague C; Duchateau L
Efficacy of and tolerance to Exemestane (E) versus Tamoxifen (T) in 1st line hormone therapy (HT) of postmenopausal metastatic breast cancer (MBC) patients (pts): a European orgnisation for the research and treatment of cancer (EORTC breast group) phase II trial with Pharmacia and Upjohn
2001 ►
-
Bonnefoi H; Biganzoli L; Mauriac L; Čufer T; Yague C; Hebert D; Piccart M
An EORTC-IDBBC phase I study of cyclophosphamide (C) and epirubicin (E) in combination with capecitabine (X) (CEX) as primary treatment of locally advanced / inflammatory (LA/I) or large operable (LO) breast cancer (BC)
2001 ►
-
Lohrisch C; Paridaens R; Dirix LY; Beex L; Nooij M; Cameron D; Biganzoli L; Čufer T; Yague C; Duchateau L
Adverse impact on serum lipids of the irreversible aromatase inactivator Aromasin (Exemestane (E)) in 1st line treatment of metastatic breast cancer (MBC): companion study to a European organization of research and treatment of cancer (Breast group) trial with Pharmacias' Upjohn
2001 ►
-
Awada A; Nooij M; Biganzoli L; Čufer T; Beek L; Batter V; Piccart MJ
A phase I study of continuous infusion 5-fluorouracil (F-intu) in combination with gemcitabine (GEM) in patients (pts) with anthracycline- (A) refractory or A- and taxane- (T) pretreated metastatic breast cancer (MBC)
2000 ►
-
Biganzoli L; Čufer T; Fargeot P; Rapoport B; Nooij M; Duchateau L; van Hoorebeeck I; Yague C; Epelbaum R; Piccart M
Doxorubicin (A)/taxol (T): a safe regimen in terms of cardiac toxicity in the contex of an EORTC multicenter trial
2000 ►
-
Biganzoli L; Čufer T; Bruning P; Coleman R; Calvert H; Gamucci T; Twelves C; di Paola E Donato; Duchateau L; Yague C
Doxorubicin (A) / Taxol (T) versus doxorubicin /cyclophosphamide (C) as first line chemotherapy in metasttaic breast cancer (MBC): a phase III study
2000 ►
-
Bonnefoi H; Biganzoli L; Čufer T; Hamilton A; Mauriac L; Van Hoorebeeck I; Piccart M
A feasibility study of epirubicin (E) in combination with cyclophosphamide (C) and infusional 5-fluorouracil (F-infu)(CEF-infu) as primary treatment of large operable (LO) or locally advanced/inflammatory (LA/I) breast cancer (BC)
1999 ►
New search
Comments
Top of page
Institute for Biostatistics and Medical Informatics